袖状胃切除与胃旁路术后5年糖尿病结局比较:PCORNet减重研究
这项多中心队列研究纳入9710例接受Roux-en-Y胃旁路术(RYGB)或袖状胃切除术(SG)的2型糖尿病(T2DM)成人患者,比较5年糖尿病结局。RYGB组体重下降更多、T2DM缓解率略高、复发率更低、长期血糖控制更优,可为以患者为中心的手术决策提供依据。
要点
- RYGB较SG在1年和5年体重下降更多,5年时多下降8.1个百分点。
- RYGB的T2DM缓解率约高10%,5年复发风险更低(HR 0.75)。
- 5年时RYGB组HbA1c较SG组多降低0.45个百分点。
核心结论
- 在大型多中心研究中,RYGB较SG体重下降更多、T2DM缓解率略高、复发更少且长期血糖控制更优。
研究设计与样本
- 美国34个健康系统站点开展的多中心队列研究,纳入2005年1月1日至2015年9月30日接受减重手术的成人T2DM患者9710例。
- 中位随访2.7年,女性7051例(72.6%),平均年龄49.8岁,平均BMI 49.0,白人6040例(72.2%)。
主要发现
- 1年时RYGB较SG多减重6.3个百分点(95%CI 5.8-6.7),5年时多减重8.1个百分点(95%CI 6.6-9.6)。
- RYGB的T2DM缓解率约高10%(HR 1.10,95%CI 1.04-1.16)。
- 1年调整累积缓解率RYGB为59.2%(95%CI 57.7%-60.7%),SG为55.9%(95%CI 53.9%-57.9%);5年分别为86.1%(95%CI 84.7%-87.3%)和83.5%(95%CI 81.6%-85.1%)。
- 6141例缓解者中,RYGB复发率低于SG(HR 0.75,95%CI 0.67-0.84);1年复发率分别为8.4%(95%CI 7.4%-9.3%)和11.0%(95%CI 9.6%-12.4%),5年分别为33.1%(95%CI 29.6%-36.5%)和41.6%(95%CI 36.8%-46.1%)。
- 5年时RYGB组HbA1c较基线降幅比SG组多0.45个百分点(95%CI 0.27-0.63)。
临床怎么用
- 对于合并T2DM的减重手术患者,RYGB在体重下降、糖尿病缓解及长期血糖控制方面可能优于SG,可与患者共同决策术式选择。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Bariatric surgery can lead to substantial improvements in type 2 diabetes (T2DM), but outcomes vary across procedures and populations. It is unclear which bariatric procedure has the most benefits for patients with T2DM. OBJECTIVE: To evaluate associations of bariatric surgery with T2DM outcomes. DESIGN, SETTING, AND PARTICIPANTS: This cohort study was conducted in 34 US health system sites in the National Patient-Centered Clinical Research Network Bariatric Study. Adult patients with T2DM who had bariatric surgery between January 1, 2005, and September 30, 2015, were included. Data analysis was conducted from April 2017 to August 2019. INTERVENTIONS: Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG). MAIN OUTCOME AND MEASURES: Type 2 diabetes remission, T2DM relapse, percentage of total weight lost, and change in glycosylated hemoglobin (hemoglobin A1c). RESULTS: A total of 9710 patients were included (median [interquartile range] follow-up time, 2.7 [2.9] years; 7051 female patients [72.6%]; mean [SD] age, 49.8 [10.5] years; mean [SD] BMI, 49.0 [8.4]; 6040 white patients [72.2%]). Weight loss was significantly greater with RYGB than SG at 1 year (mean difference, 6.3 [95% CI, 5.8-6.7] percentage points) and 5 years (mean difference, 8.1 [95% CI, 6.6-9.6] percentage points). The T2DM remission rate was approximately 10% higher in patients who had RYGB (hazard ratio, 1.10 [95% CI, 1.04-1.16]) than those who had SG. Estimated adjusted cumulative T2DM remission rates for patients who had RYGB and SG were 59.2% (95% CI, 57.7%-60.7%) and 55.9% (95% CI, 53.9%-57.9%), respectively, at 1 year and 86.1% (95% CI, 84.7%-87.3%) and 83.5% (95% CI, 81.6%-85.1%) at 5 years postsurgery. Among 6141 patients who experienced T2DM remission, the subsequent T2DM relapse rate was lower for those who had RYGB than those who had SG (hazard ratio, 0.75 [95% CI, 0.67-0.84]). Estimated relapse rates for those who had RYGB and SG were 8.4% (95% CI, 7.4%-9.3%) and 11.0% (95% CI, 9.6%-12.4%) at 1 year and 33.1% (95% CI, 29.6%-36.5%) and 41.6% (95% CI, 36.8%-46.1%) at 5 years after surgery. At 5 years, compared with baseline, hemoglobin A1c was reduced 0.45 (95% CI, 0.27-0.63) percentage points more for patients who had RYGB vs patients who had SG. CONCLUSIONS AND RELEVANCE: In this large multicenter study, patients who had RYGB had greater weight loss, a slightly higher T2DM remission rate, less T2DM relapse, and better long-term glycemic control compared with those who had SG. These findings can help inform patient-centered surgical decision-making.
引用
- McTigue KM, Wellman R, Nauman E, et al. Comparing the 5-Year Diabetes Outcomes of Sleeve Gastrectomy and Gastric Bypass: The National Patient-Centered Clinical Research Network (PCORNet) Bariatric Study. JAMA Surg. 2020. PMID: 32129809. doi:10.1001/jamasurg.2020.0087
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。